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Abstract: Steroid hormone receptors represent a major target in drug discovery. As ligand inducible transcription factors, 
their activity can be modulated by small lipophilic molecules. Here we describe two panels of potent and selective 
luciferase reporter cell lines based on cells with low endogenous steroid receptor activity (U2OS). The panels contain 
reporter cell lines for estrogen receptors 	 and 
, androgen, glucocorticoid, mineralocorticoid, and progesterone receptors. 
In the first panel, the activation of either synthetic, steroid response elements containing promoter or viral promoter is 
mediated by full-length steroid receptors. The second panel is based on the expression of the chimeric receptor, which was 
created by the replacement of the N-terminal part of the molecule by Gal4 DBD and that binds to multiple UAS sites in 
the reporter promoter. Both panels were extensively characterized by profiling 28 ligands in dose response manner in 
agonist and antagonist mode. We have analyzed and compared the responses to tested ligands from both panels and 
concluded that in general both systems generated similar qualitative response in terms of potency, efficacy, partial 
agonism/antagonism, mixed agonistic/antagonistic profiles and the rank of potencies was well conserved between both 
panels. However, we have also identified some artifacts introduced by the Gal4/LBD reporter assays in contrast to their 
full-length receptor reporter counterparts. Keeping in mind the advantages and drawbacks of each reporter format, these 
cell lines represent powerful and selective tools for profiling large compound libraries (HTS) and for detailed study of 
mechanisms by which compounds exert their biological effects. 
Keywords:  U2OS, cell-based luciferase reporter assay, ligand binding domain, Gal4, nuclear hormone receptor, steroid 
receptor, HTS, drug discovery. 
INTRODUCTION 
 Steroid hormone receptors are ligand-inducible 
transcription factors belonging to nuclear hormone receptor 
superfamilly and include two receptors for estrogens (ER	 
and ER
), androgen receptor (AR), glucocorticoid receptor 
(GR), mineralocorticoid receptor (MR) and progesterone 
receptor (PR) [1]. They control essential physiological, 
developmental, reproductive and metabolic processes. In 
addition to their indisputable numerous roles in the 
physiology of healthy organisms, a growing body of work 
indicates they also represent an important pharmaceutical 
target in number of diseases including cancer. For instance, 
ER	 and PR are important targets in the breast cancer [2, 3], 
while AR is the major therapeutic target in prostate tumors 
[4]. Ligands antagonizing natural hormone ligands for these 
receptors with reduced side effects are intensively sought as 
potential drugs for cancer treatment. On the other hand anti-
inflammatory properties of GR agonists make this group of 
ligands indispensable in combating inflammation associated 
with many diseases [5]. Finally, emerging evidence for the 
tumor suppressive functions of ER
 in many cancers like 
breast [6], colon [7], ovarian [8] and prostate [9] cancer 
make the ER
 selective agonists promising drugs for the 
future treatment of these tumors. 
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  Steroid hormone receptor activity can be regulated in 
many different ways including posttranslational 
modifications resulting from cell signaling activity, for 
example phosphorylation of target proteins. Expression of 
different set of coactivator or corepressor molecules and the 
activity of other transcription factors can be responsible for 
different transcriptional regulation by steroid receptors in 
different cellular contexts [10]. However, small lipophilic 
molecules acting as ligands for these receptors are the main 
and the most powerful means to modulate steroid receptor 
activity. In the process of drug and biologically active 
compound discovery, different approaches are commonly 
used. These include variety of biochemical assays where the 
main criterion for identification of active compounds is the 
binding affinity of the compound to the receptor. Although 
this approach generates unambiguous data, it provides only 
very limited information about qualitative changes that the 
compound induces in the receptor conformation and 
therefore is difficult to assess the effect of the compound on 
the transcription of target genes by the receptor. Cell-based 
reporter assays overcome this limitation and provide more 
complex information about the compound-receptor 
interaction and enrich it by reflecting other dimensions of 
steroid receptor activity such as promoter-receptor 
interactions, cofactor-receptor recruitment and finally 
crosstalk with other cellular pathways. Cell-based reporter 
assays provide rich and complex information that makes 
them one of the most relevant and important assays for 
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  Several luciferase reporter systems have been developed 
recently using different cell lines [11-14]. Here we report on 
a development of two panels of U2OS-based luciferase 
steroid receptor reporter cell lines using two different 
reporter formats. In the first format the activity of full-length 
exogenous steroid receptor is monitored by reporter vector 
containing synthetic promoter with multimerized responsive 
elements or viral LTR promoter upstream of the luc2 gene. 
The second format relies on the chimeric steroid receptor 
where the N-terminal part of the receptor containing AF-1 
and DNA binding domain (DBD) was replaced by the DBD 
from the yeast transcription factor Gal4. This construct was 
cotransfected to the cells together with reporter vector 
containing 9 copies of Gal4 Upstream Activator Sequences 
(UAS) coupled to minimal promoter upstream of the luc2P 
gene coding for the luciferase with PEST destabilizing 
sequence (pGL4.35 [luc2P/9XGAL4UAS/Hygro]). This 
system was described recently, and its utility was illustrated 
by preparation of ER and GR reporter assays in HEK293 
cells [13]. In this work we extended this system to all 
members of the steroid receptor family and built a panel of 
selective reporter cell-lines in U2OS cells. Both of these 
formats use the latest generation of pGL4 reporter vector 
backbone [15]. 
MATERIALS AND METHODS 
Compounds and Reagents 
  Diethylstilbestrol (DES), 17-estradiol (E2), 4-hydroxy-
tamoxifen (4-OHT), raloxifene hydrochloride, tamoxifen 
citrate, ICI 182.780, genistein, (R,R)-cis-diethyltetrahydro-
2,8-chrysenediol (R,R-THC), beclomethasone, betametha-
sone, dexamethasone, cortisol, triamcinolone, 5-androstan-
17-ol-3-one (DHT, dihydrotestosterone), testosterone, cyp-
roterone acetate, danazol, flutamide, nilutamide, spironolac-
tone, aldosterone, corticosterone, 17-hydroxyprogesterone, 
mifepristone (RU486), progesterone were purchased from 
Sigma-Aldrich (St. Louis, MO, USA); DPN and propyl 
pyrazole triol (PPT) were from Tocris Bioscience (Bristol, 
UK), promegestone (R5020) from PerkinElmer (Waltham, 
MA); Phenol red-free Dulbecco´s Modified Eagle Medium 
(DMEM) and Fetal Bovine Serum (FBS) were from 
Invitrogen (Carlsbad, CA, USA); Hyclone Charcoal/Dextran 
Treated Fetal Bovine Serum (C/D FBS) from Thermo Fisher 
Scientific Inc. (Waltham, MA, USA). One-Glo Luciferase 
Assay System was obtained from Promega Corporation 
(Madison, WI, USA). 
Vectors 
  Expression vectors encoding human full-length 
steroid receptors: pcDNA3-hER: coding sequence for 
human ER was excised from the pSG5-HE0 [16] with 
EcoRI and cloned into pcDNA3 expression vector (Invitro-
gen, Carlsbad, CA, USA) behind the Cytomegalovirus 
(CMV) promoter. pcDNA3-hER: coding sequence for 
human ER was RT-PCR amplified from human hemato-
poietic progenitor cells (CFU-C) total RNA with following 
primers: 5´ CCGCATTTTAGAGAAGGCAAGGCCGG 3´ 
and 5´ACTGGAGTTCACG CTTCAGCCTGTGACCTC 3´. 
Amplified DNA was then inserted into the pcDNA3 
expression vector. pcDNA3-hGR and pcDNA3-hAR: DNA 
encoding human GR and AR was ordered from 
Openbiosystems (Huntsville, AL, USA) (clone ID: 4810424 
and 40146997). pcDNA3-hGR was created by transferring 
the DNA portion encoding GR to BamHI and XhoI sites in 
the pcDNA3 vector. DNA coding for AR was excised from 
the parental vector, blunt-ended and inserted into EcoRV site 
in the pcDNA3 vector. Final constructs were verified by 
restriction digests and by sequencing. pcDNA3-hMR was 
described previously [17] and was provided as a gift by 
Marie-Edith Rafestin-Oblin (INSERM, France). 
  Expression vectors encoding chimeric receptors 
consisting of Gal4-DBD and of the ligand binding domain 
(LBD) of the human steroid receptor: Creation of pBIND-
ER
G420C and pBIND-GR in pFN26A (BIND) vector was 
described earlier [13]. 
 For  pBIND-ER
wt, a DNA sequence of ER-LBD 
(amino acids 303-595) based on GenBank NM_000125 was 
synthesized by DNA 2.0 (Menlo Park, CA), and cloned into 
pFN26A (BIND) hRluc-neo (Promega) using SgfI and PmeI 
so that the SgfI site yields an in-frame protein fusion with 
GAL4-DBD. 
 ER-LBD was cloned by PCR amplification of the 
region comprising ER-LBD and a piece of the hinge region 
using previously cloned full-length ER as template and 
following primers: 5´AACAGCGATCGCCCAGGCCTGCC 
GACTTCGGAAG 3´ and 5´ AGAA GTTTAAACCTGAGA 
CTGTGGGTTCTGGGAGCC 3´. Similarly AR-LBD was 
cloned using previously cloned full-length AR as template, 
and the following primers were used for the amplification of 
the LBD region: 5´ AACAGCGATCGCCGCCCGGAAGC 
TGAA GAAACTTGG 3´ and 5´ AGAAGTTTAAACCT 
GGGTGTGGAAATAGATGGGCTTG 3´. MR-LBD was 
cloned by RT-PCR from total RNA isolated from HEK293 
cells using following primer combination: 5´ AACAGCGA 
TCGCCCCCTCGGTCAACACAGCACTGG 3´ and 5´ 
AGAAGTTTAAACCTTCCGGTGGAAGTAGAGCGGC 
3´. Plasmid encoding human PR was purchased from 
Openbiosystems (clone ID: 100016179), and PR-LBD 
region was PCR amplified using the following primer 
combination: 5´ AACAGCGATCGCCGAAAGCCAAGCC 
CTAAGC CAGAG 3´ and 5´ AGAAGTTTAAACCTTTTT 
ATGAAAGAGAAGGGGTTTCACC 3´. PCR products with 
steroid receptor LBDs were digested by SgfI/PmeI and 
inserted into SgfI/PmeI sites in the pFN26A (BIND) vector. 
Final constructs were verified by restriction digests and 
sequencing. 
 Reporter  vectors: pGL4.26-3xERE [luc2/Hygro] was 
created by inserting an oligonucleotide comprising three 
copies of estrogen responsive elements (ERE) CCAGGTC 
ACAGTGACCTGAGT in the pGL4.26 [luc2/minP/Hygro] 
reporter vector (Promega, Madison, WI, USA). In this 
synthetic estrogen responsive promoter the centers of the 
perfect palindromic inverted repeats are separated by 21 bp 
from each other. The 3xERE containing oligonucleotide was 
inserted in the XhoI/BglII restriction sites of pGL4.26 
[luc2/minP/Hygro] reporter vector. pGL4.26-3xGRE 
[luc2/Hygro] was constructed in a similar way by insertion 
of an oligonucleotide containing three copies of glucocorti-
coid responsive elements (GRE) GGTACATTTTGTT 
CTAGCCAG in the XhoI/BglII restriction sites of pGL4.26 
[luc2/minP/Hygro] reporter vector. 250   Combinatorial Chemistry & High Throughput Screening, 2011, Vol. 14, No. 4  Sedlák et al. 
 pGL4.35  [luc2P/9XGAL4UAS/Hygro] and pGL4.36 
[luc2P/MMTV/Hygro] reporter vectors were described 
previously [13]. 
  Final constructs were verified by restriction digests and 
sequencing. 
Generation of Stable Reporter Cell-Lines 
  The production of stable reporter cell lines for both full-
length steroid hormone receptors and chimeric steroid LBD 
receptors in U2OS cells was done in two steps. In the first 
step, U2OS cells were transfected with reporter vector alone 
(pGL4.26-3xERE [luc2/Hygro], pGL4.26-3xGRE [luc2/ 
Hygro], pGL4.36 [luc2P/MMTV/Hygro] or pGL4.35 [luc2P/ 
9XGAL4UAS/Hygro]) using PEI 25kDa (PolySciences, Inc., 
Warrington, PA, USA) transfection. Two days after 
transfection, selection of stable transfectants was initiated by 
adding Hygromycin B (Invitrogen, Carlsbad, CA, USA) to 
the culture medium at final concentration of 100 μg/ml. Cells 
were grown in the Hygromycin B-containing medium for 
three weeks, and after that time cells were frozen and were 
used later for transfection with expression vectors for steroid 
receptors. 
  Panel of U2OS Steroid receptor-LBD/9xGal4UAS 
luciferase reporter cell-lines: U2OS cell line stably 
transfected with pGL4.35 [luc2P/9XGAL4UAS/Hygro] was 
transfected with expression vectors for chimeric steroid 
receptors: pBIND-ER
wt, pBIND-ER
G420C, pBIND-ER, 
pBIND-AR, pBIND-GR, pBIND-MR and pBIND-PR to 
give rise to the following reporter cell-lines: U2OS-ER
wt-
LBD/9xGal4UAS, U2OS-ER
G420C-LBD/9xGal4UAS, U2OS- 
ER-LBD/9xGal4UAS, U2OS-AR-LBD/9xGal4UAS, U2OS- 
GR-LBD/9xGal4UAS, U2OS-MR-LBD/9xGal4UAS and 
U2OS-PR-LBD/9xGal4UAS, respectively. In order to create 
U2OS-AR-LBD/9xGal4UAS cell line, we cotransfected 
pBIND-AR vector together with pcDNA3-hAR vector in the 
10:1 ratio of the DNA amount in the transfection mixture. 
Two days after transfection, selection of stable transfectants 
was initiated by adding G418 and Hygromycin B 
(Invitrogen, Carlsbad, CA, USA) to the culture medium at 
final concentration of 250 μg/ml and 100 μg/ml respectively. 
Cells were propagated in the medium containing antibiotics 
for at least two months before being frozen and used for 
compound profiling. 
  Panel of U2OS full-length steroid receptor luciferase 
reporter cell-lines: U2OS cell line stably transfected with 
pGL4.26-3xERE [luc2/Hygro] was transfected with expres-
sion vectors encoding full-length steroid receptors: pcDNA3-
hER and pcDNA3-ER, creating U2OS-ER/3xERE and 
U2OS-hER/3xERE cell lines, respectively. U2OS cell line 
stably transfected with pGL4.26-3xGRE [luc2/Hygro] was 
transfected with expression vectors encoding full-length 
steroid receptors: pcDNA3-hAR and pcDNA3-hGR, creating 
U2OS-AR/3xGRE and U2OS-GR/3xGRE cell lines, 
respectively. U2OS cell line stably transfected with pGL4.36 
[luc2P/MMTV/Hygro] was transfected with expression 
vectors encoding full-length steroid receptors: pcDNA3-
hAR, pcDNA3-hGR and pcDNA3-hMR to generate U2OS-
AR/MMTV, U2OS-GR/MMTV, U2OS-MR/MMTV repor-
ter cell lines, respectively. Two days after transfection, 
selection of stable transfectants was initiated by adding G418 
and Hygromycin B (Invitrogen, Carlsbad, CA, USA) to the 
culture medium at final concentration of 250 μg/ml and 100 
μg/ml respectively. Cells were propagated in the antibiotics 
containing medium for at least two months before being 
frozen in liquid nitrogen and profiled with different 
compounds. 
Luciferase Reporter Assay 
  The luciferase assay was performed in the high 
throughput screening (HTS) 384-well format using HTS 
instruments: U2OS stable reporter cell lines were propagated 
in a monolayer in phenol red-free DMEM supplemented 
with 10% fetal bovine serum, 4 mM glutamine (Invitrogen, 
Carlsbad, CA, USA) and penicillin/streptomycin and 
incubated in a 5% CO2 humidified atmosphere at 37°C. 
Forty-eight hours preceding experiments, growth medium 
was changed for phenol red-free DMEM supplemented with 
4% C/D FBS and 4 mM glutamine (starvation medium). 
After that time, cells were trypsinized, counted and seeded at 
a density of 10
4 cells/well in white opaque cell culture 384-
well plates (Corning Inc., NY, USA). Compounds to be 
tested were serially diluted in DMSO and stored in the 
polypropylene 384-well plates (Corning Inc., NY, USA). 
The concentration of serially diluted compounds was in the 
range of 10 mM to 0.1 nM and each compound was tested at 
least in 12 different concentrations. They were transferred to 
cells by JANUS Automated Workstation (PerkinElmer, Inc.) 
equipped with Pin tool (V&P Scientific, Inc., San Diego, 
CA, USA). During the Pin tool transfer of compounds from 
the concentrated DMSO stocks to the culture medium, 
compounds were 1000x diluted. After incubation for 20 
hours, the luciferase activity was determined using One-Glo 
Luciferase Assay System (Promega, Madison, WI, USA) 
according to the manufacturer´s protocol. In the antagonist 
mode, cells were incubated for 30 min with specific agonist 
at specified concentration prior to Pin tool compound 
transfer. Luminescence was recorded on EnVision plate 
reader (PerkinElmer, Inc.) using 1s integration of 
luminescent signal. The experiment was repeated at least 
three times. Data were analyzed by GraphPad Prism 5.0 
statistical software and LogEC50/LogIC50 values were 
generated by fitting data from the luciferase reporter assay 
by nonlinear regression function (dose response, variable 
slope). Values are reported as mean ± standard error of the 
mean (SEM). 
RESULTS 
Creation of U2OS Reporter Cell Lines 
  To build the full-length steroid receptor reporter system 
we created two reporter vectors carrying synthetic promoters 
with three copies of either estrogen responsive element 
(ERE) or glucocorticoid responsive element (GRE) coupled 
to a minimal promoter upstream of the coding sequence for 
the luciferase. ERE and GRE are constituted by the perfect 
palindromic repeats with a three bp spacing of variable 
bases. The centers of palindromes are separated by 21 bp 
from each other, and the distance of the third repeat from the 
minimal promoter is 50 bp. ER and ER bind to EREs in 
the promoter of the reporter vector pGL4.26-3xERE 
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used to monitor activity of the remaining steroid receptors: 
GR, MR, AR and PR. Although all of these receptors can 
activate the luciferase gene in the presence of the agonist by 
binding to GRE elements in the reporter vector, the response 
was not equally efficient in all of these cases. For instance, 
MR showed only weak transactivation on the 3xGRE-
containing synthetic promoter. To overcome these 
limitations, we combined these receptors with pGL4.36 
[luc2P/MMTV/Hygro] reporter vector, which contains the 
enhancer region from the mouse mammary tumor virus long 
terminal repeat (MMTV LTR) promoter. This region was 
originally isolated as progesterone and glucocorticoid 
responsive enhancer [18], but it is also highly inducible by 
AR and MR. The use of this reporter vector resulted in 
generally higher dynamic range and higher robustness of the 
reporter assay. However, the complexity of the viral 
promoter and presence of responsive elements for other 
cellular transcription factor add a higher probability of cross-
talk with different signaling pathways. 
  Cross-talk with different signaling pathways is not the 
only technical problem that needs to be carefully considered 
during data analysis. Cross-talk with endogenously 
expressed steroid receptors can be even more important issue 
because ER and ER bind to the same response elements, 
and GR, MR, AR and PR activate more or less efficiently 
promoters in both reporter vectors. When creating selective 
reporter cell lines, it is essential to express exogenous steroid 
receptors in cell lines with low background activity of other 
members of this receptor class. Unfortunately many of the 
cell lines traditionally used in the individual steroid receptor 
research do not fulfill this condition, and they could be only 
used in the study of small subset of receptors in the same 
time due to the endogenous expression of other steroid 
receptors. In order to create robust and selective reporter 
assays that would ideally be based on single parental cell 
line, we screened several commonly used cell lines for 
endogenous steroid receptor activity (Fig. 1). Not 
surprisingly it was difficult to find a cell line with null 
background activity for all steroid receptors. For instance, 
COS7 cells derived from kidney of African green monkey 
and CHO cells from Chinese hamster ovary are often used in 
the study of ERs, which is in agreement with our observation 
that they have no ER activity. On the other hand COS7 cells 
are responsive to progesterone and CHO cells to cortisol and 
aldosterone when transfected with GRE containing reporter 
vector suggesting that they express nonnegligible levels of 
PR and GR/MR, respectively. In HEK 293 cells we found 
GR activity. No detectable activity of any steroid receptor 
was found in U2OS cells that was in agreement with 
previous observations [14]. In addition, these cells are easy 
to maintain and expand in cell culture and therefore are 
excellent for building up the panel of selective reporter cell 
lines. 
  As a starting point we have created four master cell lines 
stably transfected by following reporter vectors: pGL4.26-
3xERE [luc2/Hygro], pGL4.26-3xGRE [luc2/Hygro], 
pGL4.36 [luc2P/MMTV/Hygro] and pGL4.35 [luc2P/9XGA 
L4UAS/Hygro]. These master cell lines were later 
transfected with corresponding expression vectors and the 
resulting reporter cell lines established after selection of 
resistant clones with antibiotics are listed in the Table 1 
(supplementary material). To make sure that all cell lines are 
stable and do not change properties such as dynamic range or 
potency when exposed to ligands, they were cultured in the 
antibiotics containing medium for at least two months before 
freezing them and using them for compound profiling. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Activity of endogenous steroid receptors in commonly 
used cell lines. Selected cell lines (COS 7, U2OS, CHO, HEK 293 
and K562) were transfected either with pGL4.26-3xERE 
[luc2/Hygro] or pGL4.26-3xGRE [luc2/Hygro] in the starvation 
medium and 24 hours after transfection cells were transferred to the 
white opaque 96-well plate at 2x10
4 cells/well. Cells transfected 
with pGL4.26-3xERE [luc2/Hygro] were exposed to different 
concentrations of 17-estradiol while cells transfected with 
pGL4.26-3xGRE [luc2/Hygro] were exposed to different 
concentrations of cortisol, aldosterone, progesterone, testosterone 
and mifepristone (RU 486) for another 24 hours. Control cells were 
exposed only to the diluent (DMSO). Luciferase activity was finally 
measured using ONE-Glo™ reagent (Promega) and fold induction 
was calculated as a ratio of the luciferase activity of cells treated 
with ligands and those treated with DMSO only. For clarity fold 
inductions are represented in the color scale. 
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Compound Profiling 
  To validate these cell lines with respect to their utility to 
detect agonistic and antagonistic properties of compounds, 
we used them for profiling a set of 28 well-established 
ligands, comprising both natural ligands and synthetic 
compounds, commonly used in clinics or as potent tools in 
the study of steroid receptors. The profiling was performed 
in the agonist and antagonist mode, and LogEC50/LogIC50 
values calculated from dose response curves (Figs. 2, 3 and 
data not shown) are summarized in the Table 1. 
Characterization of Full-Length Steroid Receptor 
Reporter Cell Lines 
  Generally all U2OS reporter cell lines expressing full-
length steroid receptors were sensitive to their commonly 
used agonists and antagonists. EC50 values varied between 1 
pM and 100 pM for the following combinations ER/E2, 
ER/E2, AR/DHT and MR/aldosterone and the potency of 
GR-expressing reporter cell lines was close to 1 nM for 
dexamethasone: EC50 (U2OS-GR/3xGRE) = 1.66 nM and 
EC50 (U2OS-GR/MMTV) = 1.03 nM (Table 1e). The lower 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Transcriptional response of ER luciferase reporter cell lines to selected compounds. Different responses of ER luciferase reporter 
cell lines to selected compounds were obtained by the incubation of the cells with increasing concentrations of tested compounds for 20 
hours. At the end of this time luciferase activity was measured. Values are expressed as a percentage of the maximal activation of the 
reporter system by E2. U2OS-ER/3xERE (), U2OS-ER
wt-LBD/9xGal4UAS () and U2OS-ER
G420C-LBD/9xGal4UAS cells () were 
tested with E2 (A), DES (B) and PPT (C) in the agonist mode and with ICI 182.780 (D), raloxifene hydrochloride (E) and tamoxifen citrate 
(F) in the presence of 1 nM E2 for U2OS-ER/3xERE, 1 nM E2 for U2OS-ER
wt-LBD/9xGal4UAS and 20 nM E2 for U2OS-ER
G420C-
LBD/9xGal4UAS in the antagonist mode. (G) U2OS-ER/3xERE reporter cell line was tested with E2 () and PPT (); U2OS-ER-
LBD/9xGal4UAS with E2 () and PPT (). (H) U2OS-ER/3xERE was tested with DPN () and genistein (); U2OS-ER-
LBD/9xGal4UAS with DPN () and genistein (). (I) Antagonistic response of U2OS-ER/3xERE reporter cell line to raloxifene 
hydrochloride () and to tamoxifen citrate ()in the presence of 1 nM E2 and the response of U2OS-ER-LBD/9xGal4UAS reporter cell 
line to raloxifene hydrochloride () and to tamoxifen citrate () in the presence of 5 nM E2. Two Panels of Steroid Receptor Luciferase Reporter Cell Lines  Combinatorial Chemistry & High Throughput Screening, 2011, Vol. 14, No. 4    253 
potency of dexamethasone and glucocorticoids more 
generally on GR (Fig. 3d, Table 1e) in comparison to 
potencies observed in the 17-estradiol induced 
transactivation by ER and ER (Fig. 2a, g and Table 1a) or 
dihydrotestosterone induced transactivation by AR (Fig. 3a 
and Table 1c) was expected and is consistent with data in the 
literature [19]. GR generally shows slightly lower affinity to 
its ligands compared to other steroid receptors. ER and ER 
reporter cell lines showed high sensitivity to estrogenic 
compounds as illustrated by 17-estradiol with potency 
attacking picomolar range: EC50(U2OS-ER/3xERE) = 4 pM 
and EC50(U2OS-ER/3xERE) = 5 pM (Table 1a). Similarly 
both AR reporter cell lines respond to dihydrotestosterone in 
the picomolar range: EC50(U2OS-AR/3xGRE) = 4 pM and 
EC50(U2OS-AR/MMTV) = 3 pM (Table 1c) and MR to 
aldosterone in the subnanomolar range: EC50(U2OS-
MR/MMTV) = 88 pM (Table 1g). We also compared data 
generated with our cell lines to values in the literature and 
found our data comparable to literature reports for all 
receptor/promoter combinations [11, 12, 14, 19-21]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Transcriptional response of AR, GR and MR luciferase reporter cell lines to selected compounds. Different responses of AR, GR 
and MR luciferase reporter cell lines to selected compounds were obtained by the incubation of the cells with increasing concentrations of 
tested compounds for 20 hours. At the end of this time luciferase activity was measured. (A) U2OS-AR/3xGRE cells were tested with 
dihydrotestosterone () and E2 (); U2OS-AR/MMTV with dihydrotestosterone () and E2 (); U2OS-AR-LBD/9xGal4UAS with 
dihydrotestosterone () and E2 (). (B) Agonistic response of U2OS-AR/3xGRE (), U2OS-AR/MMTV () and U2OS-AR-
LBD/9xGal4UAS () reporter cell lines to testosterone. (C) Antagonistic response of U2OS-AR/3xGRE (), U2OS-AR/MMTV () and 
U2OS-AR-LBD/9xGal4UAS () reporter cell lines to nilutamide in the presence of 0.05 nM, 0.05 nM and 1 nM dihydrotestosterone 
respectively. U2OS-GR/3xGRE (), U2OS-GR/MMTV () and U2OS-GR-LBD/9xGal4UAS () reporter cell lines were tested with 
cortisol (D) and betamethasone (E) in the agonist mode and with cyproterone acetate in the presence of 5 nM dexamethasone for all of the 
reporter cell lines (F). (G) U2OS-MR/MMTV reporter cell line was tested with aldosterone () and dexamethasone (); U2OS-MR-
LBD/9xGal4UAS with aldosterone () and dexamethasone (). Antagonistic response of U2OS-MR/MMTV () and U2OS-MR-
LBD/9xGal4UAS () reporter cell lines to spironolactone (H) and to dihydrotestosterone in the presence of 1 nM aldosterone for all of the 
reporter cell lines (I). 254   Combinatorial Chemistry & High Throughput Screening, 2011, Vol. 14, No. 4  Sedlák et al. 
   
Table 1.  Compound Profiling Using 28 Natural and Synthetic Ligands and ER (1a, 1b), AR (1c, 1d), GR (1e, 1f), MR (1g) and PR 
(1h) Stable Reporter Cell Lines. Log EC50 (M) and Log IC50 (M) Values were Calculated from Dose Response Curves 
Obtained from Reporter Cells Treated with Serially Diluted Compounds as Described in Materials and Methods. Values 
are Reported as Mean ± Standard Error of the Mean (SEM) 
 
Table 1a.  Compound Profiling Using ER Reporter Cell Lines in the Agonist Mode 
ER
wt-LBD/ ER
G420C-LBD/ ER-LBD/ 
   ER/3xERE 
/9xGal4UAS /9xGal4UAS 
ER/3xERE 
/9xGal4UAS 
DES  -10.94 ± 0.15  -10.75 ± 0.29  -9.33 ± 0.17  -11.06 ± 0.08  -9.22 ± 0.02 
E2 (17 –estradiol)  -11.37 ± 0.07  -11.17 ± 0.35  -9.83 ± 0.13  -11.33 ± 0.45  -9.62 ± 0.11 
4-hydroxy-tamoxifen   -10.24 ± 0.26  -10.17 ± 0.55  -8.75 ± 3.05  > -5.00  > -5.00 
Raloxifene hydrochloride  -10.35 ± 0.45  -9.83 ± 0.24  -9.41 ± 0.70  > -5.00  > -5.00 
Tamoxifen citrate  -7.96 ± 0.35  -7.43 ± 0.55  -6.61 ± 0.26  > -5.00  > -5.00 
ICI 182.780  > -5.00  > -5.00  > -5.00  > -5.00  > -5.00 
Genistein  -7.21 ± 0.09  -6.92 ± 0.16  -6.19 ± 0.15  -8.75 ± 0.31  -8.01 ± 0.23 
DPN  > -5.00  > -5.00  > -5.00  -9.65 ± 0.10  -8.38 ± 0.08 
PPT  -8.77 ± 0.13  -8.62 ± 0.25  -7.94 ± 0.31  > -5.00  > -5.00 
R.R-THC  -8.96 ± 0.10  -8.61 ± 0.45  -7.72 ± 0.25  > -5.00  > -5.00 
Beclomethasone  > -5.00  > -5.00  > -5.00  > -5.00  > -5.00 
Betamethasone  > -5.00  > -5.00  > -5.00  > -5.00  > -5.00 
Dexamethasone  > -5.00  > -5.00  > -5.00  > -5.00  > -5.00 
Cortisol  > -5.00  > -5.00  > -5.00  > -5.00  > -5.00 
Corticosterone  > -5.00  > -5.00  > -5.00  > -5.00  > -5.00 
Triamcinolone  > -5.00  > -5.00  > -5.00  > -5.00  > -5.00 
Dihydrotestosterone  -5.76 ± 0.12  -6.68 ± 0.27  -5.22 ± 0.01  -7.28 ± 0.06  -5.81 ± 0.11 
Testosterone  -4.71 ± 0.07  -5.73 ± 0.09  > -5.00  -6.31 ± 0.33  -5.54 ± 0.04 
Cyproterone acetate  > -5.00  > -5.00  > -5.00  > -5.00  > -5.00 
Danazol  -5.36 ± 0.03  -6.61 ± 0.39  > -5.00  > -5.00  > -5.00 
Flutamide  > -5.00  > -5.00  > -5.00  > -5.00  > -5.00 
Nilutamide  > -5.00  > -5.00  > -5.00  > -5.00  > -5.00 
Spironolactone  > -5.00  > -5.00  > -5.00  > -5.00  > -5.00 
Aldosterone  > -5.00  > -5.00  > -5.00  > -5.00  > -5.00 
17-hydroxy-progesterone  > -5.00  > -5.00  > -5.00  > -5.00  > -5.00 
Mifepristone (RU486)  > -5.00  > -5.00  > -5.00  > -5.00  > -5.00 
Progesterone  > -5.00  > -5.00  > -5.00  -6.50 ± 0.21  -5.31 ± 0.44 
Promegestone (R5020)  > -5.00  > -5.00  > -5.00  > -5.00  > -5.00 
 
Log  (EC50)  -11  -10 -9 -8 -7 -6 -5 
Color               
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(Table 1) contd….. 
Table 1b.  Compound Profiling Using ER Reporter Cell Lines in the Antagonist Mode 
ER
wt-LBD/ ER
G420C-LBD/ ER-LBD/ 
   ER/3xERE 
/9xGal4UAS /9xGal4UAS 
ER/3xERE 
/9xGal4UAS 
DES  > -5.00  > -5.00  > -5.00  > -5.00  > -5.00 
E2 (17 –estradiol)  > -5.00  > -5.00  > -5.00  > -5.00  > -5.00 
4-hydroxy-tamoxifen   -9.08 ± 0.32  -8.70 ± 0.40  -7.65 ± 0.09  -8.60 ± 0.06  -8.70 ± 0.09 
Raloxifene hydrochloride  -8.81 ± 0.17  -8.01 ± 0.50  -7.32 ± 0.17  -9.09 ± 0.22  -9.36 ± 0.14 
Tamoxifen citrate  -6.21 ± 0.13  -6.01 ± 0.24  -5.34 ± 0.09  -6.00 ± 0.21  -6.11 ± 0.19 
ICI 182.780  -8.48 ± 0.18  -8.60 ± 0.09  -7.00 ± 0.11  -8.35 ± 0.17  -8.53 ± 0.15 
Genistein  > -5.00  > -5.00  > -5.00  > -5.00  > -5.00 
PPT  > -5.00  > -5.00  > -5.00  -6.24 ± 0.14  -6.01 ± 0.23 
R.R-THC  -6.94 ± 0.15  -5.53 ± 0.72  -6.40 ± 0.07  -7.30 ± 0.14  -7.39 ± 0.15 
Beclomethasone  > -5.00  > -5.00  > -5.00  > -5.00  > -5.00 
Betamethasone  > -5.00  > -5.00  > -5.00  > -5.00  > -5.00 
Dexamethasone  > -5.00  > -5.00  > -5.00  > -5.00  > -5.00 
Cortisol  > -5.00  > -5.00  > -5.00  > -5.00  > -5.00 
Corticosterone  > -5.00  > -5.00  > -5.00  > -5.00  > -5.00 
Triamcinolone  > -5.00  > -5.00  > -5.00  > -5.00  > -5.00 
Dihydrotestosterone  > -5.00  > -5.00  > -5.00  > -5.00  > -5.00 
Testosterone  > -5.00  > -5.00  > -5.00  > -5.00  > -5.00 
Cyproterone acetate  -5.56 ± 0.16  > -5.00  > -5.00  > -5.00  > -5.00 
Danazol  > -5.00  > -5.00  > -5.00  > -5.00  > -5.00 
Flutamide  > -5.00  > -5.00  > -5.00  > -5.00  > -5.00 
Nilutamide  > -5.00  > -5.00  > -5.00  > -5.00  > -5.00 
Spironolactone  -6.93 ± 0.17  -6.68 ± 1.47  -5.50 ± 0.14  -5.89 ± 0.44  -5.26 ± 0.15 
Aldosterone  > -5.00  > -5.00  > -5.00  > -5.00  > -5.00 
17-hydroxy-progesterone  > -5.00  > -5.00  > -5.00  > -5.00  > -5.00 
Mifepristone (RU486)  -6.26 ± 0.52  -6.07 ± 0.25  -5.00 ± 0.21  -6.87 ± 0.20  -6.93 ± 0.56 
Progesterone  > -5.00  > -5.00  > -5.00  > -5.00  > -5.00 
Promegestone (R5020)  > -5.00  > -5.00  > -5.00  > -5.00  > -5.00 
 
Log  (EC50)  -11  -10 -9 -8 -7 -6 -5 
Color               
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(Table 1) contd….. 
Table 1c.  Compound Profiling Using AR Reporter Cell Lines in the Agonist Mode 
  AR/3xGRE AR/MMTV  AR-LBD/9xGal4UAS 
DES  > -5.00  > -5.00  > -5.00 
E2 (17 –estradiol)  -7.30 ± 0.25  -7.71 ± 0.15  > -5.50 
4-hydroxy-tamoxifen   > -5.00  > -5.00  > -5.00 
Raloxifene hydrochloride  > -5.00  > -5.00  > -5.00 
Tamoxifen citrate  > -5.00  > -5.00  > -5.00 
ICI 182.780  > -5.00  > -5.00  > -5.00 
Genistein  > -5.00  > -5.00  > -5.00 
DPN  > -5.00  > -5.00  > -5.00 
PPT  > -5.00  > -5.00  > -5.00 
R.R-THC  > -5.00  > -5.00  > -5.00 
Beclomethasone  > -5.00  > -5.00  > -5.00 
Betamethasone  > -5.00  > -5.00  > -5.00 
Dexamethasone  > -5.00  > -5.00  > -5.00 
Cortisol  > -5.00  > -5.00  > -5.00 
Corticosterone  > -5.00  -7.10 ± 0.19  > -5.00 
Triamcinolone  > -5.00  > -5.00  > -5.00 
Dihydrotestosterone  -11.38 ± 0.21  -11.58 ± 0.10  -10.36 ± 0.12 
Testosterone  -10.00 ± 0.26  -9.74 ± 0.21  -8.64 ± 0.05 
Cyproterone acetate  -8.02 ± 0.19  -7.36 ± 0.30  -7.33 ± 0.15 
Danazol  -9.38 ± 0.17  -9.63 ± 0.16  -7.97 ± 0.35 
Flutamide  > -5.00  > -5.00  > -5.00 
Nilutamide  > -5.00  > -5.00  > -5.00 
Spironolactone  -7.52 ± 0.12  -7.73 ± 0.16  -4.90 ± 0.97 
Aldosterone  > -5.00  > -5.00  > -5.00 
17-hydroxyprogesterone  > -5.00  > -5.00  > -5.00 
Mifepristone (RU486)  -7.89 ± 0.13  -8.50 ± 0.06  -8.70 ± 0.49 
Progesterone  -7.85 ± 0.11  -8.13 ± 0.17  > -5.00 
Promegestone (R5020)  > -5.00  > -5.00  > -5.00 
 
Log  (EC50)  -11  -10 -9 -8 -7 -6 -5 
Color               
EC50  0.01 nM  0.1 nM  1 nM  10 nM  100 nM  1 μM 10  μM Two Panels of Steroid Receptor Luciferase Reporter Cell Lines  Combinatorial Chemistry & High Throughput Screening, 2011, Vol. 14, No. 4    257 
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Table 1d.  Compound Profiling Using AR Reporter Cell Lines in the Antagonist Mode 
 AR/3xGRE AR/MMTV  AR-LBD/9xGal4UAS 
 DES  > -5.00  > -5.00  > -5.00 
E2 (17 –estradiol)  > -5.00  > -5.00  -6.68 ± 0.20 
4-hydroxy-tamoxifen   > -5.00  > -5.00  > -5.00 
Raloxifene hydrochloride  > -5.00  > -5.00  > -5.00 
Tamoxifen citrate  > -5.00  > -5.00  > -5.00 
ICI 182.780  > -5.00  > -5.00  > -5.00 
Genistein  > -5.00  > -5.00  > -5.00 
PPT  -6.50 ± 7.81  > -5.00  -5.24 ± 0.28 
R.R-THC  -5.26 ± 0.28  -5.22 ± 1.26  > -5.500 
Beclomethasone  > -5.00  > -5.00  > -5.00 
Betamethasone  > -5.00  > -5.00  > -5.00 
Dexamethasone  > -5.00  -5.62 ± 0.73  > -5.00 
Cortisol  > -5.00  > -5.00  > -5.00 
Corticosterone  -6.44 ± 0.96  -7.18 ± 0.60  -6.63 ± 0.47 
Triamcinolone  > -5.00  > -5.00  > -5.00 
Dihydrotestosterone  > -5.00  > -5.00  > -5.00 
Testosterone  > -5.00  > -5.00  > -5.00 
Cyproterone acetate  -7.16 ± 0.36  -8.27 ± 0.55  -6.48 ± 0.18 
Danazol  > -5.00  > -5.00  -8.24 ± 0.37 
Flutamide  -5.87 ± 0.37  -6.07 ± 0.27  -5.38 ± 6.17 
Nilutamide  -6.67 ± 0.27  -6.61 ± 0.08  -5.85 ± 0.20 
Spironolactone  -5.94 ± 0.67  > -5.00  -6.16 ± 0.11 
Aldosterone  > -5.00  > -5.00  > -5.00 
17-hydroxyprogesterone  -7.21 ± 0.52  -6.68 ± 0.13  -6.14 ± 0.21 
Mifepristone (RU486)  -7.94 ± 0.60  -7.80 ± 0.77  -6.59 ± 0.14 
Progesterone  -7.47 ± 0.34  -6.86 ± 0.25  -6.75 ± 0.17 
Promegestone (R5020)  -7.66 ± 0.18  -7.90 ± 0.13  -6.39 ± 1.51 
 
Log  (EC50)  -11  -10 -9 -8 -7 -6 -5 
Color               
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Table 1e.  Compound Profiling Using GR Reporter Cell Lines in the Agonist Mode 
 GR/3xGRE GR/MMTV  GR-LBD/9xGal4UAS 
DES  > -5.00  > -5.00  > -5.00 
E2 (17 –estradiol)  > -5.30  > -5.00  -6.40 ± 0.52 
4-hydroxy-tamoxifen   > -5.00  > -5.00  > -5.00 
Raloxifene hydrochloride  > -5.00  > -5.00  > -5.00 
Tamoxifen citrate  > -5.00  > -5.00  > -5.00 
ICI 182.780  > -5.00  > -5.00  > -5.00 
Genistein  > -5.00  > -5.00  > -5.00 
DPN  > -5.00  > -5.00  > -5.00 
PPT  > -5.00  > -5.00  > -5.00 
R.R-THC  > -5.00  > -5.00  > -5.00 
Beclomethasone  -8.98 ± 0.14  -8.43 ± 0.08  -8.50 ± 0.05 
Betamethasone  -8.95 ± 0.15  -8.11 ± 0.06  -8.57 ± 0.13 
Dexamethasone  -8.78 ± 0.28  -8.99 ± 0.08  -9.08 ± 0.03 
Cortisol  -7.34 ± 0.35  -7.27 ± 0.06  -7.22 ± 0.01 
Corticosterone  -8.23 ± 0.34  -7.57 ± 0.10  -6.57 ± 0.06 
Triamcinolone  -8.33 ± 0.12  -7.89 ± 0.07  -7.99 ± 0.04 
Dihydrotestosterone  > -5.00  > -5.00  > -5.00 
Testosterone  > -5.00  > -5.00  > -5.00 
Cyproterone acetate  -6.89 ± 0.10  -6.56 ± 0.49  > -5.00 
Danazol  > -5.00  > -5.00  > -5.00 
Flutamide  > -5.00  > -5.00  > -5.00 
Nilutamide  > -5.00  > -5.00  > -5.00 
Spironolactone  > -5.00  > -5.00  > -5.00 
Aldosterone  -7.52 ± 0.15  -6.68 ± 0.10  -5.94 ± 0.12 
17-hydroxyprogesterone  > -5.00  > -5.00  > -5.00 
Mifepristone (RU486)  -8.61 ± 0.72  -9.21 ± 0.14  > -5.00 
Progesterone  -6.87 ± 0.18  -6.85 ± 0.30  > -5.00 
Promegestone (R5020)  > -5.50  > -5.00  > -5.00 
 
Log  (EC50)  -11  -10 -9 -8 -7 -6 -5 
Color               
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Table 1f.  Compound Profiling Using GR Reporter Cell Lines in the Antagonist Mode 
 GR/3xGRE GR/MMTV  GR-LBD/9xGal4UAS 
DES  > -5.00  > -5.00  > -5.00 
E2 (17 –estradiol)  > -5.00  > -5.00  > -5.00 
4-hydroxy-tamoxifen   > -5.00  > -5.00  > -5.00 
Raloxifene hydrochloride  > -5.00  > -5.00  > -5.00 
Tamoxifen citrate  > -5.00  > -5.00  > -5.00 
ICI 182.780  > -5.00  > -5.00  > -5.00 
Genistein  > -5.00  > -5.00  > -5.00 
PPT  > -5.00  > -5.00  > -5.00 
R.R-THC  > -5.00  > -5.00  > -5.00 
Beclomethasone  > -5.00  > -5.00  > -5.00 
Betamethasone  > -5.00  > -5.00  > -5.00 
Dexamethasone  > -5.00  > -5.00  > -5.00 
Cortisol  > -5.00  > -5.00  > -5.00 
Corticosterone  > -5.00  > -5.00  -8.38 ± 0.28 
Triamcinolone  > -5.00  > -5.00  > -5.00 
Dihydrotestosterone  > -5.00  > -5.00  -5.84 ± 0.26 
Testosterone  > -5.00  > -5.00  > -5.00 
Cyproterone acetate  -6.64 ± 0.38  -6.58 ± 0.29  -6.98 ± 0.05 
Danazol  -6.25 ± 1.19  -5.51 ± 1.82  -6.11 ± 0.22 
Flutamide  > -5.00  > -5.00  > -5.00 
Nilutamide  > -5.00  > -5.00  > -5.00 
Spironolactone  -6.30 ± 0.34  > -5.00  -5.99 ± 0.26 
Aldosterone  > -5.00  > -5.00  -6.67 ± 0.60 
17-hydroxyprogesterone  > -5.00  > -5.00  > -5.00 
Mifepristone (RU486)  -8.67 ± 0.14  > -5.00  -9.46 ± 0.07 
Progesterone  > -5.00  -5.60 ± 0.70  -7.25 ± 0.23 
Promegestone (R5020)  -7.95 ± 0.57  -6.82 ± 0.24  -6.92 ± 0.19 
 
Log  (EC50)  -11  -10 -9 -8 -7 -6 -5 
Color               
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Table 1g.  Compound Profiling Using MR Reporter Cell Lines 
MR-LBD/ MR-LBD/ 
   MR/MMTV 
/9xGal4UAS 
MR/MMTV 
/9xGal4UAS 
   Agonist Mode  Antagonist Mode 
DES  > -5.00  > -5.00  > -5.00  > -5.00 
E2 (17 –estradiol)  > -5.00  > -5.00  -5.87 ± 0.26  -5.82 ± 0.04 
4-hydroxy-tamoxifen   > -5.00  > -5.00  > -5.00  > -5.00 
Raloxifene hydrochloride  > -5.00  > -5.00  > -5.00  > -5.00 
Tamoxifen citrate  > -5.00  > -5.00  > -5.00  > -5.00 
ICI 182.780  > -5.00  > -5.00  > -5.00  > -5.00 
Genistein  > -5.00  > -5.00  > -5.00  > -5.00 
DPN  > -5.00  > -5.00  > -5.00  > -5.00 
PPT  > -5.00  > -5.00  -5.30 ± 0.30  -5.12 ± 0.17 
R.R-THC  > -5.40  > -5.00  -5.45 ± 0.22  -5.08 ± 0.13 
Beclomethasone  -7.97 ± 0.12  -7.95 ± 0.10  > -5.00  -7.64 ± 0.10 
Betamethasone  -7.26 ± 0.30  -7.41 ± 0.09  > -5.00  -7.47 ± 0.09 
Dexamethasone  -8.33 ± 0.12  -7.78 ± 0.27  > -5.00  -7.68 ± 0.17 
Cortisol  -8.20 ± 0.11  -7.95 ± 0.38  > -5.00  > -5.00 
Corticosterone  -10.09 ± 0.22  -10.58 ± 0.52  > -5.00  > -5.00 
Triamcinolone  -6.73 ± 0.03  -7.12 ± 0.05  > -5.00  -6.30 ± 0.18 
Dihydrotestosterone  > -5.00  > -5.00  -6.08 ± 0.10  -6.58 ± 0.09 
Testosterone  > -5.00  > -5.00  -7.00 ± 0.32  -7.39 ± 0.30 
Cyproterone acetate  > -5.00  > -5.00  -5.19 ± 0.24  -5.97 ± 0.60 
Danazol  > -5.00  > -5.00  -5.19 ± 0.40  -5.58 ± 0.45 
Flutamide  > -5.00  > -5.00  > -5.00  > -5.00 
Nilutamide  > -5.00  > -5.00  > -5.00  > -5.00 
Spironolactone  > -5.00  > -5.00  -7.87 ± 0.15  -8.20 ± 0.09 
Aldosterone  -10.06 ± 0.26  -10.25 ± 0.05  > -5.00  > -5.00 
17-hydroxyprogesterone  -5.54 ± 0.22  -6.63 ± 0.03  > -5.00  > -5.00 
Mifepristone (RU486)  > -5.00  > -5.00  > -5.30  > -5.448 
Progesterone  > -8.00  > -5.50  -9.45 ± 0.23  -8.82 ± 0.11 
Promegestone (R5020)  > -5.00  > -5.00  -7.33 ± 0.24  -7.87 ± 0.06 
 
Log  (EC50)  -11  -10 -9 -8 -7 -6 -5 
Color               
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Table 1h.  Compound Profiling Using PR Reporter Cell Lines. 
   PR-LBD/9xGal4UAS PR-LBD/9xGal4UAS 
   Agonist Mode  Antagonist Mode 
DES  > -5.00  > -5.00 
E2 (17 –estradiol)  -6.04 ± 0.07  > -5.00 
4-hydroxy-tamoxifen   > -5.00  > -5.00 
Raloxifene hydrochloride  > -5.00  > -5.00 
Tamoxifen citrate  > -5.00  > -5.00 
ICI 182.780  > -5.00  > -5.00 
Genistein  > -5.00  > -5.00 
DPN  > -5.00  > -5.00 
PPT  -5.37 ± 0.12  > -5.00 
R.R-THC  > -5.00  -5.52 ± 0.70 
Beclomethasone  -5.20 ± 0.05  > -5.00 
Betamethasone  -5.32 ± 0.05  > -5.00 
Dexamethasone  -5.32 ± 0.02  > -5.00 
Cortisol  -5.21 ± 0.07  > -5.00 
Corticosterone  -7.14 ± 0.17  > -5.00 
Triamcinolone  -7.23 ± 0.28  > -5.00 
Dihydrotestosterone  -6.40 ± 0.08  > -5.00 
Testosterone  -7.33 ± 0.18  > -5.00 
Cyproterone acetate  -9.10 ± 0.07  -7.91 ± 0.26 
Danazol  -7.04 ± 0.13  -6.16 ± 0.28 
Flutamide  > -5.00  > -5.00 
Nilutamide  > -5.00  > -5.00 
Spironolactone  -6.25 ± 0.09  > -5.00 
Aldosterone  -5.95 ± 0.02  -5.43 ± 0.26 
17-hydroxyprogesterone  > -5.00  > -5.00 
Mifepristone (RU486)  > -5.00  -8.85 ± 0.08 
Progesterone  -9.41 ± 0.09  > -5.00 
Promegestone (R5020)  -10.89 ± 0.10  > -5.00 
 
Log  (EC50)  -11  -10 -9 -8 -7 -6 -5 
Color               
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Compound Selectivity 
  The same cellular background represented by U2OS cell 
type devoid of any endogenous steroid receptor activity 
enabled the construction of a consistent reporter system 
allowing monitoring activity of unique receptors with 
exceptional selectivity. Our data confirm this premise and 
the selectivity is illustrated by the fact that we did not find 
any sign of luciferase activity when treating ER and ER 
reporter cell lines with glucocorticoid activity-exhibiting 
compounds (dexamethasone, beclomethasone, betametha-
sone, triamcinolone, cyproterone acetate etc.) even at 10 μM 
concentration. 
  Similarly no agonistic activity was observed with GR and 
MR reporter cell lines treated with estrogens or androgens 
(Table 1e, g). Since these receptors are generally inhibited by 
estrogens, androgens and progestagens at higher 
concentrations, we detected their antagonistic activity 
especially in MR reporter cell lines. In the tested 
concentration range they can be ranked according their 
decreasing antagonistic potency to MR: progesterone > 
testosterone > dihydrotestosterone > 17-estradiol > danazol, 
PPT. 
  On the other hand we measured a weak partial agonism 
of glucocorticoids on both full-length AR reporter cell lines 
with MMTV and GRE containing promoter. The activation 
efficacy was lower than 10% of the full activation of the 
receptor by dihydrotestosterone in most cases and never 
exceeded 20% (data not shown). In addition it was stronger 
than in the master reporter cell lines U2OS-/3xGRE and 
U2OS-/MMTV, and we did not detect the same activity with 
U2OS-AR-LBD / 9xGal4UAS cell line, which is however 
less sensitive as discussed below. Therefore we hypothesize 
that the weak androgenic activation by glucocorticoids 
results from mixed activity of very low level of 
endogenously expressed GR and cross reactivity of 
glucocorticoids with AR. 
Comparison of 3xGRE Reporters Versus MMTV 
  To estimate to what extent promoter context contributes 
to different responses provoked by the same ligand and 
receptor we compared compound potencies from reporter 
cell lines which contain either synthetic promoter containing 
3xGRE or more complex viral promoter from MMTV. Two 
AR reporter cell lines show almost identical response to 
tested compounds considering the potency and efficacy of 
the dose response (r
2=0.89, Fig. 4a). Generally it can be 
noticed that U2OS-AR/MMTV is slightly more sensitive 
than U2OS-AR/3xGRE with some dose response curves 
shifted slightly to lower concentrations. Both cell lines show 
the same mixed agonistic/antagonistic profiles for 
cyproterone acetate, progesterone and mifepristone with 
comparable partial activities (Table 1c, d). 
  Very similar profiles were also obtained with GR 
reporter cell lines (r
2=0.77, Fig. 4b). We could identify few 
different responses in the antagonist mode where U2OS-
GR/MMTV was less sensitive to detect the antagonistic 
properties of some compounds like spironolactone or 
mifepristone. However, U2OS-GR/MMTV cell line provides 
about three times higher dynamic range and better data 
reproducibility (data not shown). 
Comparison of Full-Length Versus Gal4/LBD Reporter 
Formats 
  Since steroid receptors are complex molecules with 
complicated organization of the molecule one of the most 
important concerns is that removal of the N-terminal part of 
the steroid receptor molecule changes considerably the 
response to compounds. In order to see whether the 
Gal4/LBD reporter cell lines respond in the same way or 
differently to tested compounds we carefully analyzed 
potencies and partial/full activities obtained from both of 
these formats. 
ER 
 For  ER we have prepared two Gal4/LBD reporter cell 
lines: U2OS-ER
wt-LBD /9xGal4UAS and U2OS-ER
G420C-
LBD /9xGal4UAS. The second reporter cell line was 
described recently [13] and carries one amino acid 
substitution causing higher fold induction of the luciferase 
activity compared to wild type ER-LBD (data not shown) 
but also decreases the affinity of ligands to receptors by 0.5 – 
1.5 logs depending on the particular ligand (Table 1a and 
1b). There is very little difference between the response from 
U2OS-ER/3xERE and U2OS-ER
wt-LBD in both agonist 
and antagonist mode as illustrated by few examples in the 
Fig. (2a-f) and high correlation of LogEC50, LogIC50 
values obtained with these two different reporter formats 
(r
2=0.89, Fig. 4c). An exception is probably somewhat 
consistently higher potency of androgenic compounds in 
ER-LBD reporters about 1 log but these compounds 
activate ER in the micromolar and higher concentration 
range. 
ER 
  The response to compounds mediated by ER-LBD is 
shifted of about 1.5 logs to higher concentrations compared 
to full-length ER reporter (Fig. 4d, Table 1a). This shift is 
noticeable mainly in the agonist mode and is consistent in 
the whole compound collection; hence the rank of potencies 
is conserved between LBD and full-length ER reporters. It 
is worth noting that ER is considerably weaker 
transactivator than ER due to lower affinity for ERE half-
sites [22-24]. In agreement with this observation, we 
obtained only moderate fold induction of luciferase activity 
using U2OS-ER/3xERE cell line (3 to 4-fold) in contrast to 
wider dynamic range offered by U2OS-ER-
LBD/9xGal4UAS cell line (25-fold). 
GR and MR 
  With GR and MR both formats gave similar profiles with 
tested compounds in the agonist mode as shown in Table 1e, 
1g and Fig. (3d-i). When looking closely at data from both 
formats of GR reporters, we concluded that U2OS-GR-
LBD/9xGal4UAS cell line generally tends to be more 
sensitive to antagonist effect of compounds. For example 
mifepristone is partial agonist/full antagonist on both full-
length GR reporter cell lines but very potent pure full 
antagonist on LBD format. Also we didn´t detect very weak 
partial agonistic activity of progesterone using U2OS-GR-
LBD/9xGal4UAS. Similarly, MR-LBD expressing reporter Two Panels of Steroid Receptor Luciferase Reporter Cell Lines  Combinatorial Chemistry & High Throughput Screening, 2011, Vol. 14, No. 4    263 
cell line is in contrast to its full-length MR counterpart only 
weakly and partially activated by glucocorticoids such as 
dexamethasone, betamethasone and beclomethasone, and 
interestingly these compounds have pronounced full 
antagonist effect in the LBD format, while there is no sign of 
antagonistic activity in the full-length receptor format. The 
correlation between (LogEC50, Log IC50) obtained from 
different formats of GR reporters is lower than in case of 
ER or ER mainly due to the artifacts in the antagonist 
mode (r
2=0.63, Fig. 4e). These data suggest that MR-LBD 
and GR-LBD based reporter cell lines generally reproduce 
well the activity profiles of tested compounds as obtained 
using reporter cell lines expressing full-length receptors but 
in addition can produce false positives when assayed in the 
antagonist mode. 
AR 
  It was previously shown that the main transactivation 
activity inducible by ligand resides in AF-1 of the N-
terminus of the AR molecule instead of AF-2 [25-27] and 
this property makes AR unique in the steroid receptor 
family. Unfortunately this property of AR makes it also 
difficult to prepare an assay where only C-terminal part of 
the molecule containing LBD with AF-2 is used. When 
expressing the chimeric AR-LBD fused to Gal4-DBD in 
U2OS cells we were almost not able to detect any androgen-
induced luciferase activity from the reporter vector. Since the 
ligand-induced activation of AR requires the interaction 
between AF-1 and AF-2 [28, 29], we speculated that the co-
expression of the full-length AR would be sufficient for 
creating a functional AR-LBD containing transactivation 
complex able to induce transcription from the reporter vector 
containing Gal4 UAS sites. This hypothesis was confirmed 
in transient transfections and later by preparation of the 
stable reporter cell line U2OS-AR-LBD/9xGal4UAS by 
cotransfecting pBIND-AR construct together with pcDNA3-
hAR vector. This cell line however showed decreased 
sensitivity to tested compounds as illustrated by Fig. (3a, b, 
c) and Table 1c. The dose response curve is shifted in 
average about 1 log to higher concentrations for high affinity 
ligands. We also noticed that the dose response profile of 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (4). Comparison of different reporter formats and promoters. The effect of the different promoter use in the full-length AR (A) and GR 
(B) reporter assays was analyzed by correlating LogEC50 and LogIC50 values of compounds active in the reporter assays containing GRE in 
the reporter promoter and the same values obtained from reporters with MMTV promoter. Pearson correlation coefficient was calculated: AR 
(Pearson r coefficient = 0.95, r
2 = 0.89, P < 0.0001), GR (Pearson r coefficient = 0.88, r
2 = 0.77, P < 0.0001). Correlation of compound 
potencies obtained from different reporter formats. LogEC50 together with LogIC50 values of compounds active in the ER (C), ER (D) and 
GR (E) full-length reporter assays were plotted against the same values obtained from Gal4/LBD reporter assays. Pearson correlation 
coefficient was calculated: ER (Pearson r coefficient = 0.94, r
2 = 0.89, P < 0.0001), ER (Pearson r coefficient = 0.91, r
2 = 0.82, P < 
0.0001), GR (Pearson r coefficient = 0.80, r
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low affinity ligands diverged more substantially from 
profiles obtained by full-length AR reporter cell lines as 
illustrated by partial activation of AR-LBD by E2 (Fig. 3a) 
and other compounds like spironolactone, cyproterone 
acetate and danazol. 
DISCUSSION AND CONCLUSION 
  We have created and subsequently characterized two 
panels of U2OS-based luciferase steroid receptor reporter 
cell lines using two different reporter formats: Gal4/LBD 
reporter cell lines and full-length steroid receptor reporter 
cell lines. We have characterized these cell lines by profiling 
them using a set of 28 well established ligands and analyzed 
their properties in terms of compound potency, efficacy, 
selectivity and reproducibility of results among different 
formats. 
  The main advantage of the whole system is that it is 
based on single cell type: osteosarcoma U2OS cell line, and 
therefore it has unified and constant cellular background that 
is defined by the expression of the same type and amounts of 
enzymes involved in the metabolism of compounds and the 
same coactivators and corepressors regulating the steroid 
receptor transcription response. Thus results obtained from 
different reporter cell lines can be directly compared. This is 
also closely related to the selectivity of cell lines and to the 
question to what extent is the compound activity mediated 
by one given receptor. The use of uniform cellular 
background makes the estimation of contribution of different 
receptors to the measured compound activity easier since it 
is possible to test the compound on all receptors and 
compare with values from master reporter cell lines carrying 
the reporter vector alone. In addition we have shown that 
U2OS cells have no detectable activity of any of the steroid 
receptors and therefore there is no cross-talk with 
endogenously expressed receptors. This was demonstrated 
by showing selective activation of specific receptors when 
exposed to selective ligands. Taken together and considering 
the fact that U2OS cells are robust and easy to maintain in 
culture, these properties makes the whole reporter system 
highly consistent, selective and robust. 
  As a next step we have carefully compared and analyzed 
data obtained using both assay formats. The advantage of 
full-length steroid receptor reporter system is that it is based 
on the native fully functional receptors that can bind to high 
affinity response elements in the promoter of the reporter 
vectors. Because some receptors interact with the DNA and 
change their conformation according to the response 
element, we have also prepared reporter cell lines for AR, 
GR and MR where the defined response element (3xGRE) 
was replaced by the complex viral promoter derived from the 
MMTV LTR. Although we have noticed subtle differences 
between the cell lines using MMTV instead of 3xGRE, 
generally the use of MMTV provided the same information 
about the compound activity, improved dynamic range of the 
assay and reproducibility of data but also increased the risk 
of integrating signals from other signaling pathways via 
binding sites for different cellular transcription factors. 
  The problem of using overexpression of the fully 
biologically active full-length steroid receptors is potential 
lower tolerance of higher expression levels by the cells. As a 
result cells expressing higher levels of the specific receptor 
are usually unstable in the culture and the dynamic range of 
the assay might be limited from this reason. 
  Another problem with full-length receptors is that they 
respond to multiple stimuli from within the cell, and their 
activity can be modulated indirectly by posttranslational 
modifications mainly on the N-terminal part of the molecule 
as a result of activation of the other signaling pathways such 
as MAPK and PKA, for example. 
  These problems are not associated with the Gal4/LBD 
reporter format since the activity is mediated through 
Gal4/UAS response elements foreign to most of the 
mammalian transcription factors, and consequently this 
format has generally low background activity. Moreover the 
N-terminal AF-1 with regulatory sequences was removed 
from the chimeric receptors, and therefore the connection 
between the biological activity of the compound and the 
measured luciferase activity is more tightly associated with 
the specific activity of the steroid receptor as a result of 
direct compound binding. 
  The comparison of compound profiles from Gal4/LBD 
reporter assays with those from full-length receptor reporter 
assays showed that there is a high consensus between these 
two formats especially for ER, ER and GR. Although 
some Gal4/LBD reporter cell lines suffer from slightly 
decreased potency (0.5-1.5 logs) like U2OS-ER
G420C-
LBD/9xGal4UAS, U2OS-ER-LBD/9xGal4UAS and 
U2OS-AR-LBD/9xGal4UAS the rank of potencies of tested 
compounds is surprisingly well conserved. We have however 
identified few weak points of this format in U2OS-GR-
LBD/9xGal4UAS and U2OS-MR-LBD/9xGal4UAS. 
Inactive or purely agonistic compounds in the full-length 
format tended to show antagonistic properties when assayed 
with U2OS-GR-LBD/9xGal4UAS. The effect was even 
more pronounced with U2OS-MR-LBD/9xGal4UAS where 
some compounds exhibited both decreased potency and 
efficacy in the agonist mode and became full antagonists in 
the opposite mode. In other words MR-LBD and GR-LBD-
based reporters generally reproduce the activity profiles of 
some compounds compared to full-length receptor reporters, 
but can produce false positives when tested in the antagonist 
mode. 
  On the other hand Gal4/LBD reporters reflected 
surprisingly reliably some subtle activity characteristics of 
compounds such as partial agonism. For example genistein, 
ER selective isoflavone was almost full agonist in U2OS-
ER/3xERE assay, partial agonist in U2OS-ER/3xERE 
assay, full agonist in both U2OS-ER
G420C-LBD/9xGal4UAS 
and U2OS-ER-LBD/9xGal4UAS assay and partial agonist 
in U2OS-ER-LBD/9xGal4UAS assay reflecting clearly and 
perfectly the response from full-length receptors (data not 
shown). Similarly weak partial agonism of selective estrogen 
receptor modulators (SERMs) such as 4-hydroxy-tamoxifen, 
tamoxifen citrate or raloxifene hydrochloride was also 
detected using Gal4/LBD assays although it was less 
pronounced than in full-length receptor reporter format 
(Table 1a). 
  The expression of chimeric receptors is generally well 
tolerated by the host cell and considerably improves the 
dynamic range of the reporter assays compared to its full-Two Panels of Steroid Receptor Luciferase Reporter Cell Lines  Combinatorial Chemistry & High Throughput Screening, 2011, Vol. 14, No. 4    265 
length receptor counterpart with one exception being AR, 
where the removal of N-terminus causes almost complete 
silencing of the ligand induced transactivation as discussed 
above. 
  From these reasons Gal4/LBD reporter format is 
especially well suited for HTS campaigns. We have 
successfully carried out the compound profiling using all 
reporter cell lines in the 384-well format using instruments 
for HTS (Pin tool robotic compound transfer). In order to 
assess the reproducibility of the recorded data we have 
calculated Z´-factor for all the reporter cell lines in the 
Gal4/LBD reporter format (Table 1b, supplementary 
material). Z´-factor exceeding 0.5 is commonly accepted 
criterion for the satisfactory assay quality for the HTS [30]. 
Four out of eight Gal4/LBD reporter assays exhibit Z´-factor 
in the range of 0.76 and 0.80 which is a sign of an excellent 
cell-based assay very well adapted to HTS. Only two 
reporter assays showed Z´-factor lower than 0.7: U2OS-
ER
wt-LBD/9xGal4UAS and U2OS-AR-LBD/9xGal4UAS. 
The relatively low fold induction of the ER
wt-LBD reporter 
assay causing lower Z´-factor (0.65) was mentioned above 
and can be overcome by the introduction of the G420C 
mutation to the ER molecule (full-length receptor amino 
acid numbering). The resulting reporter assay (U2OS-
ER
G420C-LBD/9xGal4UAS) has 10 times higher fold 
induction (data not shown) and higher Z´-factor (0.76). In 
addition the Gal4/LBD reporter assays can benefit from the 
constitutive  expression of a Renilla  luciferase-neo
R
  fusion 
gene which can be used as an internal control in the HTS and 
can be helpful in compensating for variability between 
samples caused by difference in cell number for example by 
random pipetting errors or by nonspecific interference with 
the luciferase reporter readout and cytotoxic effects of 
compounds [13]. 
  Because each of these formats represents specific set of 
advantages and drawbacks, altogether they embody a 
powerful and complete tool for profiling of large compound 
libraries and identifying modulators showing interesting and 
useful activity profiles over the whole family of steroid 
hormone receptors. They are also sophisticated tools for the 
detailed study of mechanisms by which these compounds 
modulate the activity of the specific steroid receptors. 
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